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Abstract Churg--Strauss syndrome (CSS) is a systemic necrotizing vasculitis of the small and
medium vessels, associated with extravascular eosinophilic granulomas, peripheral eosinophilia
and asthma.
This is a rare syndrome of unknown etiology, affecting both genders and all age groups.
CSS patients usually respond well to steroid treatment, although relapses are common after
it ends. Timely diagnosis and treatment generally lead to a good prognosis with a 90% survival
rate at one year.
A brief review of CSS is presented, with particular attention to diagnosis, therapy and recent
developments in this area.
The authors then report and discuss the clinical, laboratory and imaging characteristics of
four patients admitted to an Internal Medicine Department with this diagnosis. The treatment,
response and follow-up of the cases are also described.
© 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.
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Síndrome de Churg-Strauss: casuística
Resumo A síndrome de Churg-Strauss (SCS) é uma vasculite sistémica necrotizante, que afeta
os vasos de pequeno e médio calibre e se associa a granulomas eosinofílicos extravasculares,
eosinoﬁlia periférica e asma.Casuística É uma síndrome rara, de etiologia desconhecida e que afeta ambos os géneros e todos os
grupos etários.
mente apresentam boa resposta à terapêutica com glucocorticoides,Os doentes com SCS geral
embora as recidivas sejam frequentes após a sua suspensão. O diagnóstico e terapêutica atem-
pada levam geralmente a um bom prognóstico, com uma sobrevivência de 90% um ano após o
diagnóstico.
 Please cite this article as: Alfaro TM. Síndrome de Churg-Strauss: casuística. Rev Port Pneumol. 2012;
oi:10.1016/j.rppneu.2011.12.001
∗ Corresponding author.
E-mail address: alfarotm@gmail.com (T.M. Alfaro).
173-5115/$ – see front matter © 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.
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Neste artigo é apresentada uma breve revisão da SCS, com particular atenc¸ão ao diagnóstico,
terapêutica e progressos recentes nesta área.
De seguida, os autores apresentam e discutem as características clínicas, laboratoriais e
imagiológicas de quatro doentes internados num Servic¸o de Medicina Interna com este diagnós-
tico. O tratamento instituído, as respostas observadas e o seguimento dos casos são também
descritos.
© 2011 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
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Deﬁnition and epidemiology
Churg--Strauss syndrome (CSS), also called granulomatous
and allergic angiitis is a necrotizing systemic vasculitis,
which was ﬁrst described in 1951 by the pathologists J. Churg
and L. Strauss in an autopsy series of patients with severe
asthma.1 These patients had hypereosinophilia and sys-
temic vasculitis with the histological examination showing
extravascular granulomas, tissue eosinophilia and necrotiz-
ing vasculitis.
Further case reports led to an improvement in the
deﬁnition; the American College of Rheumatology (ACR)
classiﬁcation criteria in patients with biopsy proven vasculi-
tis is the most widely used today.2 These criteria include
asthma, greater than 10% peripheral eosinophilia, mono
or polyneuropathy, migratory pulmonary inﬁltrates, sinus
anomalies and extravascular eosinophils in the biopsy. The
presence of four of these criteria in a patient with biopsy
proven vasculitis has a sensitivity of 85% and a speciﬁcity of
99.7% for CSS.2
CSS is a very rare disease, with an incidence of 1--7 cases
per million per year.3,4 The disease affects both genders
equally and can present at any age, with an average age
of 50 at presentation.5,6
Etiology
The etiology of CSS is unknown. Proposed hypotheses include
an auto-immune process, possibly associated with genetic
and environmental factors.7
In the last decade, the leukotriene receptor antagonists
(LTRAs), including zaﬁrlukast and montelukast have been
reported to be associated with the development of CSS.
This is probably related to steroid withdrawal after starting
LTRAs in patients with hitherto attenuated CSS or the pre-
scription of LTRAs to patients with worsening asthma which
was actually unrecognized worsening CSS.8,9 In fact there
have been reports of CSS after starting inhaled steroids10
and omalizumab11 and a recent case crossover study showed
that several asthma control medications are associated with
the onset of CSS, supporting the hypothesis that an aggra-
vation of asthma is associated with CSS onset, rather than a
speciﬁc drug.12Pathophysiology
The pathophysiology of CSS is not sufﬁciently well known.
A particular feature of the disease is the prominent blood
o
i
p
ond tissue eosinophilia which is related to the activity of
he disease.13 In patients with active disease, eosinophils
xpress surface markers of activation14 and secrete pro-
eins that lead to tissue injury.15 The eosinophilia seems
o be maintained by increased release of IL-5, produced
ainly by activated Th2 lymphocytes.16 In effect, the anti-
L5 antibody mepolizumab turned out to be effective in
efractory CSS in a recent study.17 Although CSS is mainly
ssociated with a Th2 proﬁle, recent studies have also shown
ossible imbalances in the activity of Th1,18 T regulatory19
nd Th17 lymphocyte lineages.20 Anti-neutrophil cytoplas-
ic antibodies (ANCAs), speciﬁcally anti-myeloperoxidase
ntibodies seem to have a pathogenic role in the vasculitic
esions, possibly through the activation of neutrophils lead-
ng to the release of reactive oxygen species and proteolytic
nzymes.21 The proposed roles of eosinophils and ANCAs
n disease pathogenesis are in agreement with the recent
eports of different disease manifestations in ANCA-positive
nd ANCA-negative patients.
linical manifestations
he clinical manifestations of CSS are generally described in
hree stages.
The ﬁrst stage (prodromal stage) can last for several
ears. Atopic asthma and rhinitis are the predominant fea-
ures, usually difﬁcult to control.
In the second stage (eosinophilic stage), an intense tissue
nﬁltration by eosinophils is seen in various organs, including
he lungs and gastro-intestinal (GI) tract, eventually evolv-
ng into Loefﬂer’s syndrome or eosinophilic gastroenteritis.
The third (vasculitic) stage of the disease is characterized
y an intense systemic vasculitis, with general symptoms
sually predating the involvement of various organs by this
rocess.22
One of the systems that is frequently affected by the
asculitis is the peripheral nervous system, with involve-
ent of the vasa vasorum and development of mononeuritis
ultiplex.23 The GI tract is also affected, with abdominal
ain, gastroenteritis or even full-blown acute abdomen as
ymptoms.24 Cardiac involvement can present as myocardi-
is, heart failure, pericarditis, or even coronary vasculitis
nd consequent myocardial ischemia. About half of all the
SS associated deaths are caused by cardiac lesions.25The
espiratory system is involved in virtually all patients, not
nly with asthma in the ﬁrst clinical stage, but also with
nﬁltrates in the chest X-ray, that are present in 37--77% of
atients. Pleural effusion can also be seen in up to a third
f the patients.26--28
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Clinically signiﬁcant renal disease is both less frequent
nd serious in CSS than in other types of vasculitis.24
isease subtypes
ecent studies have demonstrated the existence of two
iscrete CSS patient populations. ANCA positive patients
40% in these studies) present more frequently with vasculi-
is related manifestations, including renal and peripheral
ervous system involvement as well as alveolar hemor-
hage, purpura and vasculitis in the biopsy. ANCA negative
atients more frequently have manifestations related to
osinophil inﬁltration, including cardiac, pulmonary and sys-
emic symptoms. It is still unclear how relevant these new
ndings are for the therapy and prognosis of CSS.29
aboratory ﬁndings and diagnosis
he diagnosis of CSS is generally dependent on histologi-
al analysis, although this may not be needed if the patient
as eosinophilia and the typical clinical manifestations.
he most frequent tissue samples come from the GI tract
eosinophilic enterocolitis with necrotizing or granuloma-
ous vasculitis), and from the skin, where several patterns
f lesion can be seen (even in the same patient), including
xtravascular granulomas, leukocytoclastic vasculitis and
utaneous polyarteritis nodosa.
Nerve biopsies frequently demonstrate necrotizing
pineural vasculitis. The lung is also frequently sampled,
evealing patterns of bronchial asthma, eosinophilic pneu-
onia and extravascular granulomatosis.30--32
The two most suggestive and frequent histological ﬁnd-
ngs of CSS are necrotizing vasculitis and extravascular
ecrotizing granulomas, with eosinophilic inﬁltrates. These
ndings, however, are not pathognomonic.33
Blood tests show a signiﬁcant increase in inﬂammation
arkers and intense peripheral eosinophilia. The titers of
gE and rheumatoid factor are also frequently elevated.
NCAs are typically present (40--70% of patients), showing a
erinuclear pattern in almost all cases (p-ANCAs).5
The differential diagnosis includes hypereosinophilic
diopathic syndrome, chronic eosinophilic pneumonia and
arious other forms of systemic vasculitis.5,34,35
reatment
he treatment of CSS is similar to various other small-
essel vasculitis. High dose steroids are the mainstay of
reatment and generally begin with a dose of 1mg/Kg/day
max 60mg/day) of prednisolone, maintained until symp-
oms are controlled and then slowly tapered (for one
ear). In patients with factors which have a poor prognosis
central nervous system, renal, cardiac or gastro-intestinal
nvolvement), the combination of steroids and cyclophos-
hamide produced better control and sustained remission
ates,6 compared to steroids alone and is therefore included
or remission induction in the European League Against
heumatism (EULAR) recommendations for the management
f small and medium vessel vasculitis. In non-organ threat-
ning or non-life threatening disease, the same document
t
a
h
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ecommends the use of methotrexate as a less toxic alterna-
ive to cyclophosphamide. For remission maintenance, the
ombination of low-dose steroids and azathioprine, leﬂuno-
ide or methotrexate is used.36
Patients not responding or who relapse despite appro-
riate therapy are managed with different therapies,
ncluding mycophenolate mofetil,37 human intravenous
mmunoglobulin,38 and biological agents including
ituximab39, interferon-alpha,40,41 and mepolizumab.17,42
rognosis
n the absence of treatment, CSS can be rapidly fatal after
asculitis has set in. Treatment with steroids leads to a sig-
iﬁcant response in 90% of patients, although about 20% will
eed additional cytotoxic therapy.
Treatment dramatically changes the prognosis of CSS
atients (over 90% survival in one year). Nevertheless, fol-
owing suspension of steroids, recurrent disease is observed
n up to 25% of patients in the ﬁrst ﬁve years, with asthma
nd sinusitis being the most frequent manifestations.43 Most
ecurrences show a good response to steroids. The leading
ause of chronic morbidity in patients with CSS is neurolog-
cal disease.37,43
Mortality in CSS patients is usually the result of car-
iac or GI involvement, with myocarditis, heart failure,
ericarditis, or even coronary vasculitis in the former and
emorrhage, perforation or entero-colic necrosis in the lat-
er. Hemorrhagic stroke can also be a cause of death.
Through the analysis of a large number of CSS cases,
uillevin et al. recognized ﬁve factors associated with a
orse prognosis, if they are present at the time of diagnosis
cardiomyopathy, CNS involvement, severe GI disease, renal
ailure with creatinine over 1.58mg/dl and proteinuria over
g/day).44
ethods
ll patients admitted to the Department of Internal Medicine
uring a 24-year period fulﬁlling ACR diagnosis criteria for
SS were included. The clinical laboratory, imaging and
ollow-up data was attained through the analysis of the clin-
cal ﬁles.
esults
atients
our patients were included (2M/2F), with an average age
f 48 years (34--60) at diagnosis.
ase summaries
atient 1. A 46-year-old female patient presented with
eight loss, paresthesia, myalgia, arthralgia and loss of mus-
ular strength in her lower limbs in the previous month,
nd abdominal pain, diarrhea, fever and night sweats in
he last four days. She also complained of productive cough
nd worsening dyspnea in the last few days. Past medical
istory included asthma and sinusitis in the last two years.
hysical examination revealed maculo-papular lesions in the
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Table 1 Patients clinical characteristics at the time of diagnosis.
Patient 1 2 3 4
Age 46 34 60 53
Gender F M F M
Asthma (years) + (2) + (4) + (9) + (3)
Sinusitis + + + +
Systemic symptoms + + + +
Peripheral nervous system MM PN PN RP
Gastrointestinal + − + +
Cardiovascular − − − +
Renal − − − −
Skin + + − +
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pMM: mononeuritis multiplex, PN: polyneuropathy, RP: radiculopat
left foot, generalized hyporreﬂexia, and loss of muscular
strength in the lower limbs. Blood tests showed marked
eosinophilia and skin biopsy showed signs of vasculitis with
eosinophils in vessel walls. Treatment with high dose oral
prednisolone and cyclophosphamide led to a rapid response
and the patient remained asymptomatic. Three years later
she had a relapse and was treated with the same regimen,
with good results.
Patient 2. A 34-year-old male patient was admitted due to
complaints of asthenia, anorexia, diffuse myalgia and weight
loss in the last three weeks. He also complained of dyspnea,
cough with sputum and skin lesions in the lower limbs. Medi-
cal history was signiﬁcant for asthma and sinus disease with
polyposis for 4 years. Physical exam was compatible with
polyneuropathy. Blood tests revealed signiﬁcant eosinophilia
and chest CT revealed a pulmonary inﬁltrate. Skin biopsy
revealed aspects of Churg--Strauss granuloma and extravas-
cular eosinophils caused. There was a rapid and signiﬁcant
improvement after treatment with high dose prednisolone
and the patient remains on follow-up for controlled asthma.
Patient 3. A 60-year-old female patient presented having
suffered from pain and paresthesia in the left hand and right
leg for the previous week, and abdominal pain and diar-
rhea for two months. She had been diagnosed with asthma
and rhinitis for 9 years. On neurological exam she displayed
ataxia and loss of muscular strength in the lower limbs.
Blood tests revealed marked eosinophilia and chest imaging
showed migratory pulmonary inﬁltrates. Biopsy of colonic
mucosa was compatible with eosinophilic colitis. She was
treated with prednisolone and gabapentine, and later IV
cyclophosphamide but maintained signiﬁcant neurological
complaints. This led to the use of IV human immunoglobulin
with improvement after 6 cycles.
Patient 4. A 53-year-old male admitted for a 4-month
history of cutaneous vasculitis in the lower limbs, and
abdominal pain and diarrhea in the previous month. Past
medical history included asthma for three years, alcohol
abuse until 18 months earlier and dilated myocardiopa-
thy with severe heart failure for two years. Physical
exam showed hyporreﬂexia, hypoesthesia and lower limbs
petechiae. Blood tests revealed eosinophilia and sinus
CT showed signs of sinusitis. Biopsy of colonic mucosa
was compatible with eosinophilic colitis and skin biopsy
showed eosinophilic vasculitis. Treatment with prednisolone
caused rapid improvement of all complaints, but the
t
H
m
hatient died two weeks after release, of undetermined
ause.
escription of case series
linical characteristics. The patients’ clinical characteris-
ics are summarized in Table 1.
All patients had systemic, pulmonary and nervous system
nvolvement. Systemic symptoms included fever, weight loss
nd diffuse myalgia. All patients had asthma, and two also
ad complaints of worsening dyspnea and productive cough.
lthough only two patients complained of paresthesia, on
xamination all had neurological abnormalities, including
uscle weakness in two patients and hypoesthesia in all four.
he GI tract was affected in three patients, with diarrhea
nd abdominal pain.
Skin changes were found in three patients (signs of vas-
ulitis in the lower limbs).
Only one patient had cardiac involvement, which was
ost likely prior to CSS, since it had started before all
ymptoms except for asthma and was probably associated
ith chronic alcohol abuse. No renal, ophthalmic or joint
bnormalities were reported in any patient. Neither was CNS
nvolvement described.
ast medical history. Past medical history was signiﬁcant
or previously diagnosed asthma in all patients, two of them
edicated with LTRAs. One patient also had dilated myocar-
iopathy with severe heart failure, probably due to chronic
lcohol abuse.
aboratory abnormalities. The summary of laboratory
haracteristics of all patients is presented in Table 2.
All patients had leukocytosis and eosinophilia at the time
f diagnosis, with the peripheral blood eosinophils varying
etween 7800 and 35,000G/L. Erythrocyte sedimentation
ate was elevated in three patients. The levels of IgE were
uantiﬁed in three patients and were elevated in two of
hem. Three patients were tested for ANCAs, but none was
ositive.
Three of the patients had relevant changes in the chest
-ray, although only one showing migratory inﬁltrates gen-
rally associated with CSS. Chest CT was performed in three
atients revealing abnormalities in both the interstitium and
he large bronchi (Fig. 1).
istological analysis. All patients had a histological conﬁr-
ation of the vasculitis diagnosis. Two had skin biopsy, one
ad colonic mucosal biopsy and the fourth had both skin
90 T.M. Alfaro et al.
Table 2 Patients laboratory characteristics.
Patient 1 2 3 4
Peripheral leukocytes (cells/mm3) 26,500 19,100 44,200 15,800
Peripheral eosinophils (cells/mm3) 10,600 8800 35,300 7800
ESR (mm) 56 53 17 82
CRP (mg/dl) N/A 5.9 3 9
Rheumatoid factor (UI/ml) N/A 0 2650 301
IgE (UI/ml) N/A 8950 0 2,320
ANCAs N/A Neg Neg Neg
ESR: erythrocyte sedimentation rate, CRP: C reactive protein− normal
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oigure 1 High resolution computer tomography of patient 1
howing a parenchymal inﬁltrate in the lingula and left inferior
obe as well as peribronchovascular interstitial thickening.
nd colonic mucosal biopsies. Biopsies of the colonic mucosa
howed aspects of active eosinophilic colitis (Fig. 2) and skin
iopsies revealed aspects of eosinophilic vasculitis in two
atients and typical aspects of the Churg--Strauss granuloma
n another.
reatment. All patients received treatment with high
oses of systemic steroids (≥1mg/kg/day of prednisolone
r equivalent).
An immediate and relevant response to the treat-
ent was seen in all patients, with improvement in all
ut the neurological complaints within two to four days.
a
b
t
igure 2 Colonic (left) and skin (right) biopsies showing a dense in
f skin vessels (HE 400×).< 0.5, IgE: total immunoglobulin E, N/A: not available.
roublesome neurological symptoms required the addition
f another drug in three patients, namely cyclophosphamide
n one case, gabapentine in another and gabapentine and
yclophosphamide, followed by gabapentine and human
mmunoglobulin in another.
ollow-up. None of the patients died while in hospital.
hree were free of symptoms when discharged from hospi-
al, 12--46 days after admission. The other patient continued
o suffer from serious neurological complaints (upper limb
aresthesia with loss of function).
One of the patients disappeared from follow-up after 3
ears. Another died two weeks after discharge, at home,
robably due to worsening severe chronic heart failure sec-
ndary to dilated myocardiopathy which had been present
efore diagnosis of CSS. The other two patients are still in
ollow-up; one of them (patient 3) still suffers from asthma
nd intense upper member paresthesia which only improved
fter 6 cycles of endovenous human immunoglobulin. The
ther patient (patient 2) only suffers from asthma.
elapses. Only one relapse was recorded, in patient 1,
hree years after diagnosis, characterized by complaints of
olyarthralgias and cutaneous lesions, and leukocytosis with
osinophilia, which all responded well to treatment with
rednisolone and cyclophosphamide.
iscussion
he demographic and clinical characteristics of our patients
re similar to those in previously published series.45--47
The fact that two of the patients were taking LTRAs
efore the diagnosis of CSS is not particularly relevant, since
hese drugs are frequently prescribed to patients suffering
ﬁltrate of eosinophils both in the colon mucosa and in the walls
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from atopic asthma, as they are to patients with CSS. A
detailed discussion of the association between LTRAs and
CSS is beyond the scope of this article and can be found
elsewhere.9
It is important however to underline the high rate of
neurological involvement in our patients, although only one
presented the classical ﬁnding of mononeuritis multiplex.
Radiculopathy has already been described in a patient with
CSS, but seems to be a rare ﬁnding.48
It is interesting that none of blood tests of the three
patients were positive for ANCA, unlike in most published
series. This is probably due to the small number of patients
in our case series.
The difﬁculty in treatment of neurological complications
is also relevant, although this has also been discussed in
other series. The good results obtained with the use of
immunoglobulin, after failure of steroids, gabapentine and
cyclophosphamide have been previously described.49
Although extensive follow-up information was only avail-
able for two patients, the absence of mortality during
hospital admission is consistent with the good prognosis
reported in the literature for CSS, where there is timely and
correct diagnosis and therapy. Although one patient died 2
weeks after discharge, this was probably due to his existing
heart condition.
In conclusion, CSS is a rare but easily diagnosed disease
if there is a high level of clinical suspicion. It is impor-
tant that all clinicians dealing with patients with asthma or
vasculitis are aware of the clinical imaging and laboratory
characteristics of this disease, as timely and appropriate
treatment has signiﬁcant impact on both quality of life and
survival.
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